JP2010505801A5 - - Google Patents

Download PDF

Info

Publication number
JP2010505801A5
JP2010505801A5 JP2009530916A JP2009530916A JP2010505801A5 JP 2010505801 A5 JP2010505801 A5 JP 2010505801A5 JP 2009530916 A JP2009530916 A JP 2009530916A JP 2009530916 A JP2009530916 A JP 2009530916A JP 2010505801 A5 JP2010505801 A5 JP 2010505801A5
Authority
JP
Japan
Prior art keywords
vaccine
serotype
den
vaccine composition
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009530916A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010505801A (ja
JP5269796B2 (ja
Filing date
Publication date
Priority claimed from FR0608660A external-priority patent/FR2906724B1/fr
Application filed filed Critical
Publication of JP2010505801A publication Critical patent/JP2010505801A/ja
Publication of JP2010505801A5 publication Critical patent/JP2010505801A5/ja
Application granted granted Critical
Publication of JP5269796B2 publication Critical patent/JP5269796B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009530916A 2006-10-04 2007-10-02 ４種のデング血清型に対する免疫付与の方法 Expired - Fee Related JP5269796B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0608660A FR2906724B1 (fr) 2006-10-04 2006-10-04 Methode d'immunisation contre les 4 serotypes de la dengue.
FR0608660 2006-10-04
PCT/FR2007/052054 WO2008047023A2 (fr) 2006-10-04 2007-10-02 Methode d'immunisation contre les 4 serotypes de la dengue

Publications (3)

Publication Number Publication Date
JP2010505801A JP2010505801A (ja) 2010-02-25
JP2010505801A5 true JP2010505801A5 (cg-RX-API-DMAC7.html) 2010-10-28
JP5269796B2 JP5269796B2 (ja) 2013-08-21

Family

ID=38222583

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009530916A Expired - Fee Related JP5269796B2 (ja) 2006-10-04 2007-10-02 ４種のデング血清型に対する免疫付与の方法

Country Status (15)

Country Link
US (2) US7718358B2 (cg-RX-API-DMAC7.html)
EP (3) EP2077857B1 (cg-RX-API-DMAC7.html)
JP (1) JP5269796B2 (cg-RX-API-DMAC7.html)
KR (1) KR20090064593A (cg-RX-API-DMAC7.html)
CN (2) CN101553251B (cg-RX-API-DMAC7.html)
AR (1) AR063057A1 (cg-RX-API-DMAC7.html)
AU (1) AU2007311792B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0719849A2 (cg-RX-API-DMAC7.html)
CA (1) CA2663885A1 (cg-RX-API-DMAC7.html)
FR (1) FR2906724B1 (cg-RX-API-DMAC7.html)
IL (2) IL197768A0 (cg-RX-API-DMAC7.html)
MX (1) MX2009003417A (cg-RX-API-DMAC7.html)
TW (2) TWI406673B (cg-RX-API-DMAC7.html)
WO (1) WO2008047023A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200901816B (cg-RX-API-DMAC7.html)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5227172B2 (ja) * 2005-08-10 2013-07-03 サノフィ パスツール バイオロジクス リミテッド ライアビリティ カンパニー デングウイルス感染に対するワクチン接種
FR2903605A1 (fr) * 2006-07-12 2008-01-18 Sanofi Pasteur Sa Methode d'immunisation contre les quatres serotypes de la dengue
FR2909286B1 (fr) * 2006-12-01 2012-06-08 Sanofi Pasteur Methode d'immunisation contre les 4 serotypes de la dengue
ES2615390T3 (es) 2008-03-05 2017-06-06 Sanofi Pasteur Proceso para estabilizar una composición de vacuna que contiene adyuvante
EP2143440A1 (fr) * 2008-07-09 2010-01-13 Sanofi Pasteur Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués
MX343172B (es) * 2009-06-01 2016-10-26 Takeda Vaccines Inc Composiciones y metodos para administracion de vacunas contra virus del dengue.
US8968996B2 (en) 2009-06-01 2015-03-03 Takeda Vaccines, Inc. Compositions and methods for rapid immunization against dengue virus
AU2010286368B2 (en) 2009-08-31 2015-09-03 Gen-Probe Incorporated Dengue virus assay
EP2353609A1 (en) * 2010-02-04 2011-08-10 Sanofi Pasteur Immunization compositions and methods
EP2550298B1 (en) * 2010-03-23 2015-07-15 The Regents of The University of California Compositions and methods for self-adjuvanting vaccines against microbes and tumors
US9637521B2 (en) * 2011-06-29 2017-05-02 Emergex Vaccines Holdings Limited Cytotoxic T lymphocyte inducing immunogens for prevention treatment and diagnosis of dengue virus infection
TW201402143A (zh) * 2012-06-10 2014-01-16 Inviragen Inc 抗登革熱病毒疫苗之組成物及投藥方法
US8895028B2 (en) * 2012-07-20 2014-11-25 Arbovax, Inc. Methods and compositions for dengue virus 3 (DV3) infectious clone
PE20150356A1 (es) 2012-07-24 2015-03-20 Sanofi Pasteur Composiciones de vacuna para la prevencion contra la infeccion por el virus del dengue
US20150196631A1 (en) * 2012-07-24 2015-07-16 Sanofi Pasteur Vaccine compositions
WO2014083194A1 (en) 2012-11-30 2014-06-05 Sanofi Pasteur Methods for inducing antibodies
US9878031B2 (en) 2012-12-14 2018-01-30 Takeda Vaccines, Inc. Compositions, methods of administration and uses for trivalent dengue virus formulations
JP2016523251A (ja) 2013-06-21 2016-08-08 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． デングウイルスワクチン組成物およびその使用方法
TWI852899B (zh) 2014-09-02 2024-08-21 法商賽諾菲巴斯德公司 疫苗組合物
AU2015369875A1 (en) 2014-12-22 2017-06-15 Merck Sharp & Dohme Corp. Dengue virus vaccine compositions and methods of use thereof
US10857222B2 (en) 2015-07-03 2020-12-08 Sanofi Pasteur Concomitant dengue and yellow fever vaccination
KR102297300B1 (ko) * 2015-11-27 2021-09-02 케이엠 바이올로직스 가부시키가이샤 뎅기 바이러스 약독주를 뱅크화한 생바이러스, 및 그것들을 항원으로 하는 뎅기 백신
EP3691681A1 (en) 2017-10-05 2020-08-12 Sanofi Pasteur Compositions for booster vaccination against dengu
PE20211545A1 (es) 2018-09-05 2021-08-16 Takeda Vaccines Inc Dosis unitaria de vacuna contra el dengue y administracion de esta
CN114555113A (zh) 2019-08-16 2022-05-27 武田疫苗股份有限公司 用于预防登革热和甲型肝炎的方法
US20240076631A2 (en) 2020-02-27 2024-03-07 Takeda Vaccines, Inc. Method for removing host cell dna from virus preparation
WO2023147337A2 (en) 2022-01-25 2023-08-03 Takeda Vaccines, Inc. Large-scale flaviviral vaccine production and manufacture
US20250177511A1 (en) 2022-02-15 2025-06-05 Takeda Vaccines, Inc. Dengue vaccine batch mixing process
WO2023215383A1 (en) 2022-05-04 2023-11-09 Takeda Vaccines, Inc. Computer-based determination of flavivirus infectivity
EP4375381A1 (en) 2022-11-18 2024-05-29 Takeda Vaccines, Inc. A method for determining the proportion of a live, attenuated flavivirus having a nucleotide sequence comprising at least one attenuation locus in a formulation
WO2024118740A1 (en) 2022-11-29 2024-06-06 Takeda Vaccines, Inc. Large-scale flaviviral vaccine production and manufacture
WO2025072259A1 (en) 2023-09-25 2025-04-03 Takeda Vaccines, Inc. Coadministration of tetravalent dengue vaccine with hpv vaccine
WO2025122855A1 (en) 2023-12-08 2025-06-12 Takeda Vaccines, Inc. A method for determining the concentration of residual vero cell genomic dna in a sample containing virus obtained from production in vero cells

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040933A1 (en) 1995-06-07 1996-12-19 The Government Of The United States Of America, Represented By The Secretary Department Of Health And Human Services Infectious dengue 2 virus pdk-53 as quadravalent vaccine
NZ337522A (en) 1997-02-28 2001-02-23 St Chimeric flavivirus incorporating yellow fever virus modified such that a prM-E protein of a second flavivirus is expressed, and vaccines for flavivruses
EP1080370A4 (en) 1998-05-29 2003-07-30 Epimmune Inc IDENTIFICATION OF RESILIENT DR EPITOPES LARGELY REACTIVE
AU4179200A (en) 1999-03-26 2000-10-16 Walter Reed Army Institute Of Research Attenuated dengue-1 virus vaccine
EP1165128A2 (en) 1999-03-26 2002-01-02 Walter Reed Army Institute of Research Attenuated dengue-2 virus vaccine
ES2322327T3 (es) 1999-03-26 2009-06-19 Walter Reed Army Institute Of Research Vacuna multivalente contra el virus del dengue.
EP1165130A2 (en) 1999-03-26 2002-01-02 Walter Reed Army Institute of Research Attenuated dengue-3 virus vaccine
WO2000057910A1 (en) * 1999-03-26 2000-10-05 Walter Reed Army Institute Of Research Attenuated dengue-4 virus vaccine
US6632663B1 (en) 1999-09-22 2003-10-14 Aventis Pasteur Limited DNA immunization against chlamydia infection
EP1263965B1 (en) 2000-02-16 2011-09-28 The Government of the United States of America, as represented by the Secretary, Department of Health & Human Services Avirulent, immunogenic flavivirus chimeras
EP1159969A1 (fr) 2000-05-30 2001-12-05 Aventis Pasteur Vaccine composition
DK1159968T3 (da) * 2000-05-30 2009-02-23 Univ Mahidol Attenuerede stammer af Dengue-virus og deres anvendelse i en vaccinesammensætning
AT410634B (de) 2001-02-21 2003-06-25 Franz X Dr Heinz Attenuierte lebendimpfstoffe
EP1402075B1 (en) 2001-05-22 2012-11-14 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, the Department of Health and Human Services, Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses
KR20040004642A (ko) 2001-05-23 2004-01-13 덴드레온 샌 디에고 엘엘씨 세포 표면 프로테아제에 의해 활성화되는 접합체 및 이의치료학적 용도
PL371187A1 (en) 2001-06-01 2005-06-13 Acambis, Inc. Chimeric flavivirus vectors
US20040120964A1 (en) * 2001-10-29 2004-06-24 Mikszta John A. Needleless vaccination using chimeric yellow fever vaccine-vectored vaccines against heterologous flaviviruses
AU2003267937C1 (en) * 2002-01-15 2019-08-08 Sanofi Pasteur Biologics, Llc Flavivirus vaccines
WO2003101397A2 (en) * 2002-05-31 2003-12-11 Acambis, Inc. Tetravalent dengue vaccines
BRPI0408774A (pt) 2003-03-24 2006-03-28 Scripps Research Inst vacinas de dna contra crescimento tumoral e seus usos
CA2611934C (en) * 2005-06-17 2015-11-03 Sanofi Pasteur Dengue serotype 1 attenuated strain
JP5227172B2 (ja) * 2005-08-10 2013-07-03 サノフィ パスツール バイオロジクス リミテッド ライアビリティ カンパニー デングウイルス感染に対するワクチン接種
FR2903605A1 (fr) * 2006-07-12 2008-01-18 Sanofi Pasteur Sa Methode d'immunisation contre les quatres serotypes de la dengue
FR2909286B1 (fr) 2006-12-01 2012-06-08 Sanofi Pasteur Methode d'immunisation contre les 4 serotypes de la dengue

Similar Documents

Publication Publication Date Title
JP2010505801A5 (cg-RX-API-DMAC7.html)
JP2010511022A5 (cg-RX-API-DMAC7.html)
MY180698A (en) Immunization protocol against the 4 dengue serotypes
WO2008047023A3 (fr) Methode d'immunisation contre les 4 serotypes de la dengue
JP2015524421A5 (cg-RX-API-DMAC7.html)
WO2009095226A3 (en) NUCLEIC ACIDS COMPRISING FORMULA (NuGlXmGnNv)a AND DERIVATIVES THEREOF AS AN IMMUNOSTIMULATING AGENTS /ADJUVANTS
JP2007302683A5 (cg-RX-API-DMAC7.html)
IL207468A (en) HCV inhibitors and their use in the preparation of medicines for the treatment of HCV infections
JP2013542224A5 (cg-RX-API-DMAC7.html)
WO2008022196A3 (en) Development of dengue virus vaccine components
WO2009080836A3 (en) Macrocyclic indoles as hepatitis c virus inhibitors
JP2002540168A5 (cg-RX-API-DMAC7.html)
CY1112999T1 (el) Αναστολεις ιου ηπατιτιδας c
NO20090141L (no) Stabiliserte, farmasøytiske preparater som omfatter fesoterodin
MX2021002586A (es) Dosis unitaria de vacuna contra el dengue y administracion de esta.
MY184428A (en) Compositions and methods for administration of vaccines against dengue virus
NO20065190L (no) Farmasoytiske sammensetninger omfattende en amfifil stivelse
WO2006083286A3 (en) Genetically engineered swine influenza virus and uses thereof
FI3250182T3 (fi) Dispergoituvia koostumuksia
CA2915027A1 (en) Compositions and methods for administration of vaccines against dengue virus
ATE419006T1 (de) Multivalenter dengue-virus impfstoff
WO2007057763A3 (en) Nitric oxide as an anti-viral agent, vaccine and vaccine adjuvant
PH12013501373B1 (en) Bovine viral diarrhea virus type 1b vaccine compositions and methods
WO2006088481A3 (en) Genetically engineered equine influenza virus and uses thereof
JP2009515987A5 (cg-RX-API-DMAC7.html)